PDCD1 and renal carcinoma: To conclude, we provide the first report, to our knowledge, that the antidiabetic agent acarbose can impede renal tumor growth, promote anti-tumor immunity, and improve outcomes to anti-PD-1 and mTOR inhibitor-based therapeutics in preclinical renal cancer.